MedTrace Logo

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease

NCT00002714 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-05-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease.

Conditions

Interventions

BIOLOGICAL

bleomycin sulfate

DRUG

Stanford V regimen

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

mechlorethamine hydrochloride

DRUG

prednisone

DRUG

vinblastine sulfate

DRUG

vincristine sulfate

RADIATION

radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Sandra J. Horning, MD · Stanford University

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-04-30
Completion
2001-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002714 on ClinicalTrials.gov